Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
GLP-1 receptor agonists like semaglutide may be linked to a rare but serious eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), though experts say the evidence is still mixed. Two new studies in the Annals of Internal Medicine found GLP-1 users had a higher risk for ischemic optic neuropathy vs. other diabetes drugs, with older men and those with cardiovascular disease at greatest risk. Experts urge vigilance — not alarm — and stress that benefits still need to be weighed against risks.
GLP-1 receptor agonists — the blockbuster class of drugs behind Ozempic and Wegovy — are under growing scrutiny for a potential link to nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, irreversible vision loss. A narrative review published in Clinical & Experimental Ophthalmology assessed 17 studies and found "mixed" evidence: Scandinavian registry data flagged elevated NAION risk with semaglutide, while U.S. studies largely showed null or weak associations. Two additional studies in the Annals of Internal Medicine found GLP-1 users had a modestly higher risk for ischemic optic neuropathy (ION) compared to SGLT2 and DPP-4 inhibitor users — though absolute risks remained very low.
Experts stress that no causal relationship has been established, and that the overall cardiometabolic benefits of GLP-1s remain substantial. The message from clinicians is clear: awareness, not alarm.
By the Numbers:
Why it matters: With millions of patients on GLP-1 drugs — and that number growing — even rare adverse events carry significant public health weight. Clinicians should counsel patients on NAION symptoms, exercise extra caution in those who've already had NAION or are monocular, and coordinate care across specialties when weighing ocular risk against cardiovascular benefit.
